Studies showed that anti-CDK1 therapy enhanced the anti-tumor response of sorafenib in HCC patient derived xenograft (PDX) model, and provided a reasonable combination therapy to improve the clinical efficacy of sorafenib [43]. This evidence concerns the gene CDK1 and hepatocellular carcinoma.